P353: FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D-ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL

Ähnliche Einträge

• C049 | PEGASPARGASE ADMINISTRATION AND TOLERABILITY IN PATIENTS AGED 55 YEARS OR OLDER WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH THE LAL1913 PROGRAM. A SUBANALYSIS OF THE CAMPUS ALL-LAL1913 STUDY.
  von: D. Lazzarotto, et al.
  Veröffentlicht: (2025-09-01)
• P353: FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D-ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL
  von: S. Chiaretti, et al.
  Veröffentlicht: (2022-06-01)
• A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study
  von: Sabina Chiaretti, et al.
  Veröffentlicht: (2016-12-01)
• Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group
  von: Davide Lazzarotto, et al.
  Veröffentlicht: (2025-08-01)
• Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913
  von: Sabina Chiaretti, et al.
  Veröffentlicht: (2020-05-01)